20.61
price up icon0.29%   0.06
after-market Handel nachbörslich: 20.61
loading
Schlusskurs vom Vortag:
$20.55
Offen:
$20.75
24-Stunden-Volumen:
371.21K
Relative Volume:
0.80
Marktkapitalisierung:
$1.22B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-10.90
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
-3.74%
1M Leistung:
+7.34%
6M Leistung:
+12.62%
1J Leistung:
-28.88%
1-Tages-Spanne:
Value
$20.32
$20.82
1-Wochen-Bereich:
Value
$20.10
$22.36
52-Wochen-Spanne:
Value
$13.30
$29.79

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name
Firmenname
Enliven Therapeutics Inc
Name
Telefon
720-647-8519
Name
Adresse
6200 LOOKOUT ROAD, BOULDER
Name
Mitarbeiter
63
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
ELVN's Discussions on Twitter

Vergleichen Sie ELVN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ELVN
Enliven Therapeutics Inc
20.61 1.22B 0 -85.21M -68.53M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.39 108.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
463.43 60.82B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.95 61.02B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
817.32 50.01B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.81 34.05B 4.56B -176.77M 225.30M -1.7177

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-16 Eingeleitet Goldman Buy
2024-12-13 Eingeleitet BTIG Research Buy
2024-09-09 Eingeleitet H.C. Wainwright Buy
2024-06-11 Eingeleitet Robert W. Baird Outperform
2024-04-09 Eingeleitet Mizuho Buy
2023-03-29 Eingeleitet Jefferies Buy
Alle ansehen

Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten

pulisher
Oct 24, 2025

Why Enliven Therapeutics Inc. stock appeals to dividend seekers2025 Market Sentiment & Free Safe Entry Trade Signal Reports - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Real time breakdown of Enliven Therapeutics Inc. stock performanceEntry Point & AI Forecasted Entry/Exit Points - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Is Enliven Therapeutics Inc. stock a safe haven assetMarket Rally & Community Verified Watchlist Alerts - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Applying sector rotation models to Enliven Therapeutics Inc.Weekly Loss Report & Free Long-Term Investment Growth Plans - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Is Enliven Therapeutics Inc. stock cheap compared to fundamentals2025 Market Trends & Low Drawdown Investment Ideas - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Is Enliven Therapeutics Inc. stock positioned well for digital economyJuly 2025 Volume & AI Optimized Trade Strategies - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Enliven Therapeutics Inc. recovery potential after sell offQuarterly Trade Summary & Daily Price Action Insights - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 100% Upside Potential for Biotech Investors - DirectorsTalk Interviews

Oct 24, 2025
pulisher
Oct 23, 2025

Assessing Enliven Therapeutics (ELVN) Valuation as Shares Show Signs of Short-Term Momentum - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Enliven Therapeutics Insider Sold Shares Worth $276,025, According to a Recent SEC Filing - MarketScreener

Oct 23, 2025
pulisher
Oct 23, 2025

Published on: 2025-10-23 01:40:18 - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

Lyssikatos, chief scientific officer, sells Enliven Therapeutics shares By Investing.com - Investing.com Canada

Oct 22, 2025
pulisher
Oct 22, 2025

Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Price Target at $41.20 - Defense World

Oct 22, 2025
pulisher
Oct 21, 2025

Enliven Therapeutics CEO Kintz sells $266k in shares By Investing.com - Investing.com UK

Oct 21, 2025
pulisher
Oct 21, 2025

ELVN insider sale: 12,500 shares sold; 902,892 shares remain held - Stock Titan

Oct 21, 2025
pulisher
Oct 21, 2025

Is now a turning point for Enliven Therapeutics Inc.Global Markets & Risk Controlled Daily Plans - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Strategies to average down on Enliven Therapeutics Inc.Quarterly Profit Review & AI Powered Market Trend Analysis - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

How to read the order book for Enliven Therapeutics Inc.2025 Institutional Moves & Verified Entry Point Signals - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Automated trading signals detected on Enliven Therapeutics Inc.Market Sentiment Report & Free Low Drawdown Momentum Trade Ideas - newser.com

Oct 20, 2025
pulisher
Oct 18, 2025

Trading Recap: Why retail investors favor Enliven Therapeutics Inc. stockEarnings Overview Summary & Verified Momentum Stock Watchlist - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Will Enliven Therapeutics Inc. stock rally after Fed decisions2025 Key Lessons & Real-Time Chart Pattern Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Will Enliven Therapeutics Inc. stock split again soon2025 Market WrapUp & Reliable Breakout Forecasts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Will Enliven Therapeutics Inc. stock outperform tech sector in 2025July 2025 Institutional & Pattern Based Trade Signal System - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Heatmap analysis for Enliven Therapeutics Inc. and competitorsWatch List & Target Return Focused Picks - newser.com

Oct 18, 2025
pulisher
Oct 17, 2025

Why retail investors favor Enliven Therapeutics Inc. stockWeekly Loss Report & Daily Profit Focused Screening - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Will Enliven Therapeutics Inc. stock continue dividend increases2025 Performance Recap & Daily Entry Point Trade Alerts - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

(ELVN) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com

Oct 17, 2025
pulisher
Oct 17, 2025

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Investor Outlook on a Potential 89.66% Upside - DirectorsTalk Interviews

Oct 17, 2025

Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$37.26
price up icon 1.11%
$91.28
price up icon 2.21%
$29.89
price up icon 0.07%
$105.66
price up icon 0.87%
$159.66
price down icon 0.29%
biotechnology ONC
$310.81
price up icon 0.25%
Kapitalisierung:     |  Volumen (24h):